|Expense ratio (net)||N/A|
|Last cap gain||N/A|
|Morningstar risk rating||N/A|
|Beta (5Y monthly)||N/A|
|5y average return||N/A|
|Average for category||N/A|
Acerus Pharmaceuticals Corporation (the "Company" or "Acerus") (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited ("Recipharm"), a wholly-owned subsidiary of Recipharm AB (RECI-B.ST), in the Commercial Court of London. Acerus alleges that the suspension of Recipharm’s manufacturing license in August 2018, in contravention of its contractual obligations to Acerus, led to a shortage of Estrace® in Canada. In 2018, Estrace® generated sales revenues of USD$4.2M. However, due to the shortage, Estrace® revenues and Acerus’ market share have decreased substantially each year since the shortage began. Consequently, Acerus has sued Recipharm for, among other things, its loss of profits and loss of market share caused by the shortage.
Even if it's not a huge purchase, we think it was good to see that Tobias Hägglöv, the Chief Financial Officer of...
Today we will run through one way of estimating the intrinsic value of Recipharm AB (publ) (STO:RECI B) by taking the...
Unfortunately for some shareholders, the Recipharm (STO:RECI B) share price has dived 31% in the last thirty days. The...
The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have...
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
The big shareholder groups in Recipharm AB (publ) (STO:RECI B) have power over the company. Institutions will often...
How far off is Recipharm AB (publ) (STO:RECI B) from its intrinsic value? Using the most recent financial data, we'll...